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Marcelo J. Perone2 and Gregorio D. Chazenbalk1*Abstract
Multilineage differentiating stress enduring (Muse) cells, discovered in the spring of 2010 at Tohoku University in
Sendai, Japan, were quickly recognized by scientists as a possible source of pluripotent cells naturally present within
mesenchymal tissues. Muse cells normally exist in a quiescent state, singularly activated by severe cellular stress
in vitro and in vivo. Muse cells have the capacity for self-renewal while maintaining pluripotent cell characteristics
indicated by the expression of pluripotent stem cell markers. Muse cells differentiate into cells representative of all
three germ cell layers both spontaneously and under media-specific induction. In contrast to embryonic stem and
induced pluripotent stem cells, Muse cells exhibit low telomerase activity, a normal karyotype, and do not undergo
tumorigenesis once implanted in SCID mice. Muse cells efficiently home into damaged tissues and differentiate into
specific cells leading to tissue regeneration and functional recovery as described in different animal disease models
(i.e., fulminant hepatitis, muscle degeneration, skin ulcers, liver cirrhosis, cerebral stroke, vitiligo, and focal segmental
glomerulosclerosis). Circulating Muse cells have been detected in peripheral blood, with higher levels present in
stroke patients during the acute phase. Furthermore, Muse cells have inherent immunomodulatory properties,
which could contribute to tissue generation and functional repair in vivo. Genetic studies in Muse cells indicate a
highly conserved cellular mechanism as seen in more primitive organisms (yeast, Saccharomyces cerevisiae,
Caenorhabditis elegans, chlamydomonas, Torpedo californica, drosophila, etc.) in response to cellular stress and acute
injury. This review details the molecular and cellular properties of Muse cells as well as their capacity for tissue
repair and functional recovery, highlighting their potential for clinical application in regenerative medicine.
Keywords: Adult pluripotent stem cells, Muse cells, Cellular stress, Nontumorigenic, Quiescence, High homing
capacity, Regenerative medicineBackground
Gold standard pluripotent stem cells: embryonic and
induced pluripotent stem cells
Regenerative medicine is a cross-disciplinary field that
incorporates stem cell-based therapy, tissue produc-
tion and repair, and disease modeling [1]. Despite
many efforts over the last 15 years, most stem cell
trials remain clinically stagnant in their early phases
[2]. The discovery of embryonic stem (ES) cells in the* Correspondence: gchazenbalk@mednet.ucla.edu
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population with an unrestrained proliferative capacity
to differentiate into mesenchymal, ectodermal, and
endodermal lineages [3, 4]. Ethical issues quickly
arrested their upward climb. Furthermore, ES cells have
been shown to display teratoma formation and immunor-
ejection following transplantation [5]. These insurmount-
able impediments render ES cells an unrealistic
contributor to the field of regenerative medicine.
Induced pluripotent stem (iPS) cells proposed a solu-
tion to the ethical concerns that hindered ES cells.
Reprogramming adult somatic cells for intended reim-
plantation with induced expression of transcription fac-
tors generated a population of pluripotent stem cellsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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surrounding iPS cell carcinogenicity and teratoma for-
mation in vivo as a result of unbridled cell proliferation,
however, remain unresolved, precluding them from clin-
ical application [6]. The first and only trial performed in
Japan in 2015 came to a screeching halt just after the
first patient had received iPS cell treatment due to
regulatory issues surrounding the detection of harmful
mutations [7].
Potential pluripotency of adult stem cells
In the last decade, the scientific community has contin-
ued the collective effort to uncover a population of
pluripotent stem cells lacking tumorigenic properties for
utilization in cell-based therapy. In 2002, a population of
multipotent adult progenitor cells (MAPC) was reported
to be both pluripotent and nontumorigenic [8]. How-
ever, these results have yet to be reproduced. Other pop-
ulations of cells isolated from bone marrow, termed very
small embryonic-like stem cells (VSELs) and human
marrow-isolated adult multilineage inducible (MIAMI)
cells, have been shown to exhibit nontumorigenic and
pluripotent properties [8, 9]. However, these stem cell
populations remain controversial, as cell lines such as
VSELs have shown evidence of aneuploidy [10]. Further-
more, other mesenchymal stem cells (MSCs) isolated
from umbilical cord blood, referred to as unrestricted
somatic stem cells (USSCs), show epigenetic evidence of
an intermediate pluripotent phenotype while lacking ex-
pression of established pluripotent markers [11]. An-
other population of pluripotent stem cells was said to be
generated through stimulus-triggered acquisition of
pluripotency (STAP) by means of acidic exposure with
leukemia inhibitory factor (LIF) to splenic CD45+ lym-
phocytes. However, many independent investigators have
failed to reproduce this methodology, and all publica-
tions on STAP cells have since been repudiated. The ori-
ginal paper was retracted by its authors.
Mesenchymal stem cells and pluripotency
Mesenchymal tissue is vastly connected to the immune
system and contributes to inflammatory mechanisms
during tissue repair [12]. MSCs are a naturally occurring
population of nontumorigenic stem cells widely accepted
as a multipotent heterogeneous cell population. How-
ever, it has been found that MSCs undergo triploblastic
differentiation at low frequencies [13]. Several theories
have surfaced surrounding the reason why MSCs exhibit
a low degree of differentiation into other germ lineages.
MSCs constitute a heterogeneous population of cells in-
cluding endothelial cells and fibroblasts [13]. Some re-
searchers hypothesize that there could be several kinds
of stem cells within the heterogeneous MSC population
that have different germ lineage proliferative capacities.Others have speculated that a single cell population ex-
ists with the capacity to differentiate into all three germ-
lines [14].
Main text
The discovery of Muse cells
Multilineage differentiating stress enduring (Muse) cells
were first isolated from bone marrow (BM) aspirates
under long-term trypsin incubation by Dr Dezawa’s
team in 2010. Muse cells show expression of cells
double positive for CD105 (a marker of MSCs) and
SSEA3 (a marker of ES cells) [14]. Muse cells comprise
a small population of MSCs (e.g., BM-MSCs (1–2%))
[14–16], in dermal fibroblastic tissue (5%) [17], and in
adipose tissue [18–22]. Therefore, it is possible to
speculate that the unusually low frequency of pluripo-
tent cell differentiation observed in MSCs is due to the
presence of Muse cells within the total MSC population
[23].
Muse cells form characteristic cell clusters in vitro,
termed “M clusters” (Additional file 1 [22]), resembling
the formation of embryonic and iPS cells [24]. Muse
cells express pluripotent stem cell markers and self-
renewal through several generation passages [14, 16, 18,
21, 22, 25, 26].
A defining characteristic of Muse cells is their poten-
tial for triploblastic differentiation from a single cell
[15]. M clusters express pluripotent markers such as
NANOG, Oct3/4, Par-4, Sox2, and TRA1-60 in addition
to markers from mesodermal (NK2-5), endodermal
(GATAφ, α-fetoprotein), and ectodermal (MAP2) cell
lines spontaneously and under media-specific induction
[20]. Seven independent groups have confirmed this
inherent pluripotent phenotype over the last 7 years
[14, 17, 18, 21, 22, 27, 28]. These groups have found
Muse cells throughout different mesenchymal tissues
including bone marrow, skin, and adipose tissue retain-
ing the same pluripotent potential and Muse cell
phenotype [14, 17, 18].
Adipose tissue-derived Muse (Muse-AT) cells were
first identified within lipoaspirate material exposed to se-
vere cellular stress conditions such as long-term collage-
nase incubation, lack of nutrients, low temperature, and
hypoxia [18] (Fig. 1a). Remarkably, cell expansion is un-
necessary due to the large number of highly purified
Muse-AT cells (250,000–500,000 cells/g of lipoaspirate
material obtained by this technique) [18, 22]. Muse-AT
cells as well as those derived from goat skin fibroblasts
can be expanded at least 10 times without altering their
phenotype [28, 29].
Muse cells initially discovered by cell sorting from
bone marrow aspirates leads to low yield of about 1% of
Muse cells within the total population (8000 cells/ml ini-
tial culture) [14]. However, Muse-AT cells isolated by
a b c
d
e
Fig. 1 a Schematic of Muse-AT cell generation from lipoaspirate material. Different cellular components are present in adipose tissue (i.e., adipocytes,
endothelial cells (ECs), adipose stem cells (ASCs), adipose tissue macrophages, and Muse-AT cells). Adipose tissue (lipoaspirate material) first exposed to
collagenase for 30 minutes at 37 °C, and then for 12 hours under severe cellular stress conditions (i.e., long-term collagenase incubation, lack of nutrients,
low temperature, and hypoxia). Only a cluster of Muse-AT cells survived such stress. b Expression of pluripotent stem cell markers SSEA4, Oct-4, Sox-2,
and TRA1-6 in Muse-AT cells. c Expression of CD markers in Muse cells indicating an immunophenotype. d Evidence of a normal karyotype in Muse cells.
e Muse-AT cells do not form teratomas after 6-month implantation in testis (right) in comparison with control, sham-injected testis (left).
Muse-AT adipose tissue-derived multilineage differentiating stress enduring (c Reproduced from Figure 2 in Gimeno et al. [22] under CC-BY license)
(d Reproduced from Figure 4 in Gimeno et al. [22] under CC-BY license) (e Reproduced from Figure 4 in Gimeno et al. [22] under CC-BY license)
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providing potential for feasible a clinical dose of Muse
cells in humans [18, 22].
Muse-AT cells are positive for SSEA3, Oct3/4,
NANOG, and Sox2 expression [18]. Recently, another
study has confirmed the existence of Muse-AT cells with
expression of the pluripotent markers Oct4, TRA1-60,
SSEA4, NANOG, and Sox2 and their ability to self-
proliferate through five passages in vitro (Fig. 1b) [22].
Muse-AT cells spontaneously differentiate into mesoder-
mal, endodermal, and ectodermal cell lineages with an
efficiency of 23% (BODIPY+ adipocytes, SMA+ and
MyoD+ myocytes), 20% (α-fetoprotein hepatocytes, pan
keratin biliary cells), and 22% (MAP2+ neural-like cells)
respectively [18, 22]. Muse-AT cells can differentiate into
all three germline cells under specific induction differen-
tiated medium with an efficiency of 82% mesenchymal,
75% endodermal, and 78% ectodermal [18].
Muse-AT cells express low levels of genes involved in
cell proliferation as well as oncogenicity, which might
account for their low proliferative performance and lack
of tumorigenic activity [18]. Furthermore, Muse-AT cells
retain expression of several CD (clusters of differenti-
ation) markers (Fig. 1c) [18, 22]. Genetic studies across
several species (yeast, Saccharomyces cerevisiae, Caenor-
habditis elegans, chlamydomonas, Torpedo californica,drosophila, etc.) display expression of genes related to cell
death and survival, indicating a highly conserved cellular
mechanism linked to cellular stress and acute injury. This
suggests that Muse cells could play an evolutionary role in
relation to cell survival under conditions of severe cellular
stress [18, 20, 30].
Nontumorigenic activity of Muse cells
The dual nature of pluripotency and tumorigenicity re-
mains the prominent issue in identifying a cell population
best suited to cell-based regenerative therapy. California’s
Stem Cell agency along with other professional organiza-
tions define pluripotency as a cell’s potential to differenti-
ate or take on the fates of all 200 different cell types [31].
However, several groups still use in-vivo teratoma forma-
tion as a reliable method of pluripotency determination
[32]. The stringent mandatory criteria evaluates pluripo-
tency by in vivo formation of teratomas would exclude
stem cell populations exhibiting triploblastic differenti-
ation capability. The existance of pluripotent stem cells
without teratogenic activity challenges the current para-
digm that ES cells and iPS are the only pluripotent stem
cells available to be used in regenerative medicine.
Muse cells retain a stable karyotype in culture (Fig. 1d)
and low telomerase activity [14, 15, 19, 20, 22]. Further-
more, Muse cells injected into the testes of mice do not
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(Fig. 1e), making them a much more attractive candidate
than iPS cells for clinical application [14, 19, 20, 22, 23].
Cell expansion is unnecessary in the case of Muse-AT cells
due to the large number obtained from lipoaspirates
(250,000–500,000 cells/g of lipoaspirate material) [18, 22].
Muse cells show low expression of Lin28, a RNA bind-
ing protein gene involved in tumorigenesis and mainten-
ance of pluripotency [14], in contrast to ES and iPS cells
[1]. Muse cells also express high levels of Let-7, a micro-
RNA responsible for regulating embryonic development,
tumor suppression, and phenotypic differentiation, as a
potential counteracting protective mechanism against Lin
28 and against tumorigenesis [18]. A steady decline in
Lin28 is seen throughout embryonic development in com-
bination with an increase in Let-7 expression, resulting in
suppression of undifferentiated cell renewal while also
stimulating cell differentiation [33]. A high Lin28/Let-7 ra-
tio is exhibited in iPS and ES cells, likely responsible for
their tumorigenic capability in vivo [33], while Muse cells
show a high Let7/Lin28 ratio [15, 19]. We do not yet
know whether altering the Let7/Lin28 ratio would render
Muse cells to become tumorigenic, but we can predict
that decreasing the Let7/Lin28 ratio may push Muse cells
to grow at an accelerated pace and exhibit similar tumori-
genic activity as seen in iPS and ES cells [19, 33].
In contrast to ES and iPS cells, Muse cells exhibit few
epigenetic modifications. Muse cells display an increased
methylation in genes encoding for NANOG and Oct3/4
in comparison to iPS cells, which might explain their
lower expression of pluripotent stem cell markers and
suppression in teratogenic activity [15]. Muse cells there-
fore retain their plasticity while remaining nonteratogenic.
Muse cells display intrinsic immunomodulatory properties
Muse cells were primarily identified in mesenchymal tis-
sues. Connective tissue containing blood vessels carries
immune cells that provide protective support against po-
tential pathogens. Therefore, mesenchymal tissue-
resident Muse cells may locally influence the immune
response. There are strong data supporting the modula-
tory effects of MSCs in the innate and adaptive arms of
the immune system. In this respect, it is understood that
MSCs suppress T-cell proliferation and cytokine secre-
tion and regulate Th1/Th2 balance in dominant Th1-
driven diseases and animal model of diseases [34, 35],
induce regulatory T-cell (Treg) function [36], inhibit the
maturation, activation, and antigen presentation of den-
dritic cells [37], and inhibit natural killer (NK) cell pro-
liferation [38]. Similarly, pluripotent stem cells such as
ES or iPS cells demonstrated high immunomodulatory
potential by inhibition of effector T-lymphocyte prolifer-
ation including CD4+ or CD8+ T cells and NK cells [39].
The mechanisms by which MSCs promote regulatoryfunctions in immune cells are not well understood.
However, stem cell release of soluble immune modula-
tory mediators as well as contact between stem cells
and immune cells could be an effective means to
understand the mechanisms behind MSC immune
modulatory capacity [40]. Several immunomodulators
released by stem cells include hepatocyte growth factor
(HGF), transforming growth factor-β1 (TGF-β1),
indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglan-
din E2 (PGE2), heme oxygenase-1 (HO-1), interleukin-
10 (IL-10), and nitric oxide (NO) [41]. Some of these
modulatory agents can be induced and secreted after
interaction between effector immune cells and stem
cells. As an example, TGF-β seems to mediate benefi-
cial effects and suppress a Th2-driven environment
through i.v. administration of MSCs in a mouse model
of ragweed-induced asthma [42].
Regarding Muse cells, the first evidence showing their
immunomodulatory capacity was recently reported by
Gimeno et al. and Alessio et al. [22, 43]. Muse-AT cells
showed a potent immunomodulatory activity as
indicated by a decrease in proinflammatory TNF-α in
LPS-stimulated RAW 264.7 cells (a mouse macrophage-
like cell line) and freshly isolated peritoneal murine mac-
rophages incubated with Muse-AT conditioned media
in vitro. Furthermore, Muse-AT cell conditioned media
diminished the antigen-specific stimulation of Th1-type
cytokines (IFN-γ and TNF-α). In both T cells and mac-
rophages, Muse-AT cell conditioned media favored the
secretion of IL-10, a cytokine associated with regulatory
activity when expressed in immune cells [22].
TGF-β has been indicated as a key immunosuppressive
cytokine under specific circumstances and is highly
expressed in Muse-AT cells [22]. Indeed, using a small
molecule inhibitor of the type I TGF-β receptor, the im-
mune regulatory activity of Muse-AT conditioned media
on T cells and macrophages responses was reversed
almost completely [22]. To analyze further the produc-
tion of TGF-β by Muse-AT cells, the use of a neutraliz-
ing anti-TGF-β1 in the culture media of antigen-specific
stimulation of T lymphocytes reestablished IFN-γ secre-
tion (unpublished data, Fig. 2a).
Moreover, Muse-AT cell conditioned media activate
TGF-β1 signaling pathway as evidenced by high intracel-
lular levels of pSMAD2 in antigen-specific T-lymphocyte
stimulation [22]. However, whether there is a coexist-
ence of SMAD-independent signaling to control T-cell
and macrophage functions by Muse-AT cells remains to
be elucidated (Fig. 2b).
In-vivo effects of Muse cells in different animal models of
human disease
Although overwhelming evidence has shown that Muse
cells are a unique population of pluripotent
ba
Fig. 2 a TGF-β1 signaling blockade on IFN-γ secretion. Using a neutralizing monoclonal anti-TGF-β1, the inhibitory action on IFN-γ secretion was abolished
in antigen (M)-specific stimulation of T cells. T cells were obtained from transgenic NOD BDC2.5 mice. Results representative of five separate experiments
(Gimeno et al., unpublished data, 2017). b Putative intracellular signaling of TGF-β1 secreted by Muse-AT cells on T lymphocytes and macrophages. IFN-γ
interferon gamma, IL interleukin, Muse-AT adipose tissue-derived multilineage differentiating stress enduring, TGF-β1 transforming growth factor-β1
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no clinical studies have since been conducted. All studies
on Muse cells have so far been conducted through isola-
tion of Muse cells derived from humans in several mes-
enchymal tissues that regenerate damaged tissues in
different murine animal models. Since Muse cell discov-
ery in 2010, many preclinical studies have been per-
formed that could have the potential to impact the field
of regenerative medicine and disease mitigation.
Liver disease affects one in every 10 Americans each
year through cirrhosis, hepatitis, liver cancer, and other
forms [44]. Muse cells could aid in the reversal of wide-
spread liver damage and help to improve chronic liver
disease. BM-derived Muse cells successfully differentiate
into hepatocytes [16, 26]. Muse cells intravenously
injected in a damaged liver mice model, intravenous
Muse cells implant at the transection border of the hep-
atic tissue, and remain integrated, while non-Muse
counterparts (defined by SSEA3– labeling) are not de-
tected 4 weeks later [16]. Integration of Muse cells into
the damaged liver tissue was heterogeneous. A robust
amount of Muse cell integration was determined by
human-Golgi+ cells (1.89 ± 0.65% of total cells/mm2) de-
tected in the samples injected with Muse cells [16]. This
cellular integration was 48-fold higher than in samples
injected with non-Muse cells (0.04 ± 0.08% total cells/
mm2) [16]. Fluorescent labeling rules out the possibilityof Muse cell fusion with previously established hepatic
cells [16].
Intravenous infusion of Muse cells in this damaged liver
mice model shows homing and integration into localized
inflammatory sites in the liver, while abstaining from inte-
gration in other tissues besides the lungs 2 weeks post
intravenous induction [26]. Functional improvement has
been measured by a significant decrease in bilirubin pro-
duction, an increase in albumin levels, and a decrease in
fibrotic tissues as compared to non-Muse controls [26]
(Fig. 3A). Furthermore, 97% of Muse cells that incorporate
in the liver differentiate into HepPar-1-positive cells ex-
pressing human-specific albumin without any evidence of
cell fusion, showing that preimplantation induction is not
necessary due to spontaneous differentiation of Muse cells
in vivo [26].
Chronic kidney disease (CKD) has been on the rise since
the 1980s, now reaching an overall prevalence of 14% in
Americans with fewer than 20,000 transplants per year
[45]. Focal segmental glomerulosclerosis (FSGS) is a com-
mon precursor to CKD characterized by extensive scar-
ring and progressive glomerulosclerosis [46]. Recently a
group of scientists constructed a rodent model resembling
FSGS in immune-deficient SCID mice and BALB/c mice
lacking concurrent immunosuppression [46]. In both
FSGS mice models, intravenously injected Muse cells pref-
erentially integrate into damaged glomeruli as shown by
a a1
a3
c1 c2
c3
d1
d2 d3c4
a2 b1
b2 b3
b
dc
Fig. 3 A Effect of Muse cells in damaged liver. Functional improvement shown in Muse cells by a decrease in bilirubin production, increase in albumin
levels, and decrease in fibrotic tissues. B Effect of Muse cells in damaged kidney: (b1) detection of GFP(+) Muse cells distributed in different tissues after
7 weeks of injection in FSGS-SCID mice; (b2, b3) Muse cells show significant decrease in glomerular sclerosis as well as fibrotic areas. C Effect of Muse cells
in damaged neural tissue: (c1) ipsilateral sensory cortex analysis in cerebral stroke-SCID mice after 84 days of Muse, non-Muse, and vehicle treatment;
somatosensory evoked potentials show no effect in latency (c2) and significant increase in amplitude (c3) between Muse cells and vehicle controls; (c4)
integration of GFP(+) Muse cells into neural tissue at days 3 and 7 display neurite-like cell formation. D Effect of Muse cells in diabetic skin ulcers: (d1)
Muse-rich fraction shows significant reduction in percent wounded area in comparison with Muse-poor fraction at 14 days post implantation; (d2)
Muse-rich fraction expresses PECAM-1 and isolectin (markers of dermis and vascular endothelial cells) in upper dermis at 14 days post implantation; (d3)
Muse cells show negative expression of PECAM-1 and isolectin in middle and lower dermis 14 days post implantation. Muse multilineage differentiating
stress enduring, ns not significant (A Reproduced with permission from Figure 4 in Iseki et al. [26]) (b1 Reproduced with permission from Figure 2 in
Uchida et al. [46], License Number 4141730401653) (b2, b3 Reproduced with permission from Figure 6 in Uchida et al. [46], License Number
4141730401653) (c1–c3 Reproduced from Figure 6 in Uchida et al. [23] under CC-BY license) (c4 Reproduced from Figure 7 in Uchida et al. [23] under
CC-BY license) (d1 Reproduced with permission from Figure 5 in Kinoshita et al. [21], License Number 4136900281603) (d2, d3 Reproduced with
permission from Figure 7 in Kinoshita et al. [21], License Number 4136900281603)
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Muse cells/mm2 and 4.90 ± 0.21 Muse cells/mm2 at
2 weeks and 7 weeks respectively in the kidney cortex, in
contrast to non-Muse cells which mainly remain in the
spleen and lung [46] (Fig. 3B b1). Cell fusion between
Muse and host cells has been ruled out by fluorescent in-
situ hybridization, and Muse cells are detected in the
SCID mice for up to 7 weeks and in BALB/c mice for up
to 5 weeks post implantation [46]. Despite the lack ofimmunosuppressants in the BALB/c model, functional
improvement has been demonstrated through improved
urine protein, plasma creatinine levels, and creatinine
clearance at 5 weeks with no difference at 7 weeks [46]. In
comparison to non-Muse and vehicle controls, Muse cells
show significant reduction in glomerular sclerosis and
interstitial fibrosis (Fig. 3B b2, b3) [46].
Strokes are the leading cause of serious long-term dis-
ability and cost the United States approximately $33
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Muse cells contribute to neural cell regeneration and
functional recovery [23, 48, 49]. Human Muse cells are
successfully mobilized from bone marrow into blood-
stream circulation immediately following post-ischemic
stroke [27]. While Muse cells are usually mobilized into
circulation in low endogenous numbers, administering a
pure population of Muse cells could potentially produce
significant functional improvement following stroke
through efficient cell regeneration [27]. Muse cells inte-
grate into damaged neural tissue and express neuronal
factors Tuj-1 and NeuN, with relative expression of 45.3%
and 20.5% respectively, suggesting a spontaneous differen-
tiation capacity in vivo [48]. Only Muse cells incorporate
into the tissue post transplantation, exemplifying their
graft survival under stressful conditions [48].
Moreover, Muse cells successfully integrate into areas
of cerebrovascular damage due to their high resistance
to cellular stress in hematoma presence [49]. When im-
planted in vivo, post cerebral hemorrhage, Muse cells
exhibited an accelerated and significant recovery of
motor skills in mice in comparison to non-Muse con-
trols using the Morris water maze and motor function
test [49]. Muse cells integrate into neural tissue and
begin to extend neurite like outgrowths (Fig. 3C c4).
Muse cells also integrate into the motor and sensory
cortex and show functional improvement in the neural
circuit as measured by a modified neurological severity
score and rotarod test [23]. Hind-limb somatosensory
evoked potentials exhibit significantly higher amplitude
effects, indicating electrophysiological improvement,
but only a nonsignificant trend towards a higher level
of latency was found in Muse vs vehicle controls
(Fig. 3C c1–c3) [23].
Muse cells derived from dermal scalp fibroblasts dis-
play a melanocyte phenotype through expression of
melanocyte-specific antigen HMB45 following media-
specific induction [17]. An inverse correlation was
found between age and number of Muse cells isolated
from different patients, but no difference in pluripo-
tency expression was exhibited regardless of age [50].
This correlation between total Muse cell count and age
provides a contributing factor to the age effect in rela-
tive healing time, especially in surface wounds. Muse-
AT cells also successfully differentiate into dermal cells
and promote wound healing in diabetic skin ulcers
(Fig. 3D d1) [21]. Immunohistochemistry studies con-
firm that human Golgi complex-positive Muse cells
survive 14 days post implantation and differentiate into
dermis and vascular endothelial cells through PECAM-
1 and isolectin detection in the upper dermis (Fig. 3D
d2) and into other cell types as indicated by negative
PECAM-1 and isolectin in the lower and middle dermis
(Fig. 3D d3) [21].Conclusions
Significant progress has occurred since Muse cells were
introduced to the scientific community in 2010. Muse
cells express classic pluripotency markers including
SSEA-3, Oct 3/4, NANOG, Sox2, and Par-4, although at
much lower levels than ES or iPS cells. Furthermore,
Muse cells can differentiate to the three embryonic germ
layers in vitro and in vivo without teratoma formation.
Muse cells also exhibit a stable normal karyotype in cul-
ture, as indicated by their normal chromosome number
and integrity. Because naïve Muse-AT cells exist in a qui-
escent state, they are intrinsically resilient to survival when
transplanted back into the host organism. Muse cells suc-
cessfully regenerate skin, muscle, liver, kidney, and neural
damaged tissues showing high capacity of homing, inte-
gration into damaged tissues, replenishing new cells, and
restoring tissue function as demonstrated in different ani-
mal disease models. Based on their unique qualities and
vast potential, Muse cells are a very promising candidate
for tissue regeneration and stem cell therapy.
Additional file
Additional file 1: is a video showing Muse-AT cells spontaneously form
cell clusters within 24 hours (Reproduced from supplemental online
Video 1 in Gimeno et al. [22] under CC-BY license). (MP4 53529 kb)
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